Navigation Links
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
Date:5/6/2009

THOUSAND OAKS, Calif., May 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN), today announced results of voting at the company's Annual Meeting of Stockholders, held at The St. Regis Hotel, San Francisco, Calif. Approximately 87.3 percent of outstanding shares were represented at the meeting.

The director nominees: David Baltimore, Frank J. Biondi, Jr., Francois de Carbonnel, Jerry D. Choate, Vance D. Coffman, Frederick W. Gluck, Frank C. Herringer, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, Leonard D. Schaeffer and Kevin W. Sharer were each reelected to Amgen's Board of Directors, each receiving a majority of "For" votes of the votes cast. Each was elected by no less than 86.7 percent of the votes cast. With the reelection of these directors, Amgen currently has 12 directors.

With approximately 98.7 percent of "For" votes of the votes cast, stockholders ratified Ernst & Young LLP as Amgen's independent registered public accountants for the year ending Dec. 31, 2009.

Stockholders approved the Amgen 2009 Equity Incentive Plan, which authorizes the issuance of up to 100,000,000 shares of Amgen common stock. The proposal was approved with approximately 81.2 percent of votes cast "For."

Stockholders approved the proposed amendment to the company's Restated Certificate of Incorporation, as amended, to reduce the sixty-six and two-thirds percent (66-2/3%) voting requirement in the company's Restated Certificate of Incorporation, as amended, to a simple majority voting requirement for approval of certain business combinations. Approximately 84.4 percent of the outstanding shares of our common stock were in favor of the amendment.

Stockholders approved a nonbinding resolution recommending that the company amend its Amended and Restated Bylaws, as amended, to permit holders of 10 percent of the company's outstanding common stock the ability to call special meetings. The proposal received approximately 59.5 percent of the votes cast "For" the proposal. Stockholders rejected the proposal requesting that the company change its jurisdiction of incorporation from Delaware to North Dakota. The proposal received less than 3.2 percent of the votes cast "For" the proposal.

The final vote totals will be included in the company's second quarter periodic report to be filed with the Securities and Exchange Commission.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    Contacts:
    Amgen, Thousand Oaks
    David Polk: 805-447-4613 (media)
    Arvind Sood: 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
2. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
3. Amgen to Present at the Cowen and Company Annual Healthcare Conference
4. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
5. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
6. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
7. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
8. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
9. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
10. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. ... note authored by its Chairman and CEO, Jim ... the Munich Security Conference last Saturday, Bill Gates ... could kill more people than nuclear weapons. Mr. Gates ... and U.K. intelligence agencies, that scientific terrorists have access ...
(Date:2/24/2017)... BEIJING, Feb. 23, 2017 China Biologic Products, Inc. ... integrated plasma-based biopharmaceutical company in China, today announced its financial ... Fourth Quarter 2016 Financial Highlights ... increased by 21.7% in RMB terms, or increased by 13.6% ... the same quarter of 2015. Gross profit ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Drug Discovery Services portfolio to include an array of biochemical analyses critical ... reliable data to drive their hit-to-lead and SAR programs, including inhibitor potency and ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
Breaking Biology Technology:
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
Breaking Biology News(10 mins):